Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis
Open Access
- 3 December 2008
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 2 (1) , 81-88
Abstract
Objectives: Transient B cell depletion with the monoclonal anti-CD20 antibody rituximab has shown favourable clinical responses in patients with rheumatoid arthritis (RA). Recently a characteristic regeneration pattern of B cell subpopulations has been reported. However, little is known about the impact of B-cell depletion on peripheral T cells in particular regulatory T cells. Materials and Methodology: 17 patients with RA having failed anti-TNF were treated with rituximab. Four colour staining was performed using CD19, CD3, CD4, CD8, CD16, CD56, CD25, HLA-DR, HLA-G and intracellular Foxp3 at five time points spanning up to 12 months after rituximab. In addition, quantification of the soluble form of the HLA class I molecule HLA-G by ELISA has been performed. Results: Peripheral B cell depletion lasted 6 to 9 months. The absolute number of CD3+, CD4+ and CD8+ lymphocytes showed no significant changes up to 1 year after B-cell depletion compared to before therapy. Only the relative frequency for CD3 and CD4 showed a significant increase (p < 0.05). In particular, CD4+CD25++ and Foxp3 positive regulatory T cells remained constant. The percentage of HLA-G positive cells in the CD4+ or CD8+ population did not change significantly either. The amount of sHLA-G remained without significant changes. Conclusion: Absolute T cell counts showed no significant changes after rituximab compared to the time point before therapy.In particular, the frequency of regulatory T cells with a CD4+CD25++ phenotype as well as positive Foxp3 expression were numerically stable. Additionally, HLA-G positive regulatory T cells and soluble levels of HLA-G showed no significant changes.Keywords
This publication has 38 references indexed in Scilit:
- Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritisAnnals of the Rheumatic Diseases, 2009
- Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseAnnals of the Rheumatic Diseases, 2008
- The Genetic Influence of the Nonclassical MHC Molecule HLA-G on Multiple SclerosisHuman Immunology, 2007
- Cells of the synovium in rheumatoid arthritis. T lymphocytesArthritis Research & Therapy, 2007
- Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritisExpert Opinion on Pharmacotherapy, 2006
- Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritisArthritis & Rheumatism, 2006
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune DiseasesImmunobiology, 2002
- Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytesRheumatology, 2001